ScreenerHero

NUZ Neurizon Therapeutics Limited

ASX · AU · Healthcare · Biotechnology · neurizon.com
—Mkt Cap: —P/E: —

Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia. Its lead candidate is NUZ-001, a small molecule drug designed t…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.87BUSDP/E 29.6
MRNA
Moderna, Inc.
$94.42BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$81.99BUSDP/E 19.1
ARGX
argenx SE
$53.47BUSDP/E 32.5
ARGX
argenx SE
$53.22BUSDP/E 31.6
UCB
UCB SA
$44.02BUSDP/E 17.8
ONC
BeOne Medicines AG
$42.56BUSDP/E 66.4
RVMD
Revolution Medicines, Inc.
$40.57BUSD
RPRX
Royalty Pharma plc
$34.45BUSDP/E 30.4
ALNY
Alnylam Pharmaceuticals, Inc.
$31.32BUSDP/E 39.3
ROIV
Roivant Sciences Ltd.
$24.59BUSD
GMAB
Genmab A/S
$23.32BUSDP/E 31.7
GMAB
Genmab A/S
$23.26BUSDP/E 29.8
INCY
Incyte Corporation
$22.96BUSDP/E 14.0
BNTX
BioNTech SE
$22.66BUSD
INSM
Insmed Incorporated
$21.67BUSD
EXEL
Exelixis, Inc.
$15.57BUSDP/E 19.3
ASND
Ascendis Pharma A/S
$14.91BUSDP/E 17.4
JAZZ
Jazz Pharmaceuticals plc
$13.92BUSDP/E 14.7
HALO
Halozyme Therapeutics, Inc.
$13.79BUSDP/E 33.4

Key Statistics

Company
Market Cap—
Enterprise Value35.82M USD
Revenue (TTM)12.15M USD
Gross Profit12.15M USD
Net Income (TTM)-7.41M USD
Revenue/Share0.03 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU0000357261
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG0.76
EV/EBITDA-5.10
EV/Revenue2.95
P/S3.69
P/B4.82
EPS (TTM)-0.02
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin-40.78%
EBITDA Margin-57.82%
Profit Margin-60.98%
ROE-137.94%
ROA-45.31%
Growth
Revenue Growth181460.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.42M USD
CapEx (TTM)1.07K USD
FCF Margin-62.31%
FCF Yield—
Net Debt-6.50M USD
Net Debt/EBITDA0.92
Balance Sheet
Debt/Equity26.02
Current Ratio2.16
Quick Ratio2.11
Book Value/Sh0.02 AUD
Cash/Share0.02 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateOct 30, 2015
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)0.4850 AUD
Target Range0.2000 AUD – 0.7700 AUD
# Analysts2
Ownership
Shares Out.791.65M
Float531.30M
Insiders31.69%
Institutions0.00%
Technical
SMA 500.0712 AUD
SMA 2000.0756 AUD
Beta1.20
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)474.62K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—